syros.com (SYRS): Growth-Adjusted Market Cap to Net Income

Stable component supplies and laboratory contracts ensure the continuity of research at Syros Pharmaceuticals (SYRS). The historical PEG level visualizes the result of this work, where the indicator reaches 0.00. High restructuring transparency coexists with a critical shortage of funds following clinical failures. Meanwhile, a unique patent shield and the complexity of bioprocesses create significant barriers for competitors.

To build a high-quality portfolio, I utilize the PEG ratio, which correlates the P/E ratio with earnings growth rates to determine an asset's fair value based on future expansion. For Syros Pharmaceuticals (SYRS), which monetizes its gene therapy platform through partnerships with pharma behemoths, this growth-stock undervaluation metric reveals a discrepancy between the market price and the potential of its intellectual property.